Literature DB >> 11177683

Dysplasia in Barrett's Esophagus.

Marcos Pedrosa1.   

Abstract

Dysplasia is the most important marker of progression to invasive cancer in Barrett's esophagus. Intensive endoscopic surveillance with biopsy may identify invasive cancer in a patient with high-grade dysplasia (HGD). Close relationship with an experienced gastrointestinal pathologist and thoracic surgeon will improve treatment decisions and patient outcomes. No intervention is required in patients with low-grade dysplasia (LGD); continued surveillance is recommended. Surgical resection is the currently accepted therapy for high-grade dysplasia. Endoscopic ablative therapy remains experimental.

Entities:  

Year:  2001        PMID： 11177683     DOI： 10.1007/s11938-001-0048-9

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN： 1092-8472


  30 in total

1.  ACP. Best Practice No 155. Guidelines for handling oesophageal biopsies and resection specimens and their reporting.

Authors:  N B Ibrahim
Journal:  J Clin Pathol       Date:  2000-02       Impact factor: 3.411

2.  Barrett's esophagus: an overrated cancer risk factor.

Authors:  S J Spechler
Journal:  Gastroenterology       Date:  2000-08       Impact factor: 22.682

Review 3.  Photodynamic therapy in gastroenterology: current status in the year 2000.

Authors:  H C Wolfsen
Journal:  Endoscopy       Date:  2000-09       Impact factor: 10.093

Review 4.  Is there publication bias in the reporting of cancer risk in Barrett's esophagus?

Authors:  N J Shaheen; M A Crosby; E M Bozymski; R S Sandler
Journal:  Gastroenterology       Date:  2000-08       Impact factor: 22.682

Review 5.  Management of dysplasia in the columnar-lined esophagus.

Authors:  D S Levine
Journal:  Gastroenterol Clin North Am       Date:  1997-09       Impact factor: 3.806

6.  Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions.

Authors:  B J Reid; W M Weinstein; K J Lewin; R C Haggitt; G VanDeventer; L DenBesten; C E Rubin
Journal:  Gastroenterology       Date:  1988-01       Impact factor: 22.682

7.  Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus.

Authors:  C Ell; A May; L Gossner; O Pech; E Günter; G Mayer; R Henrich; M Vieth; H Müller; G Seitz; M Stolte
Journal:  Gastroenterology       Date:  2000-04       Impact factor: 22.682

8.  Endosonography in the evaluation of patients with Barrett's esophagus and high-grade dysplasia.

Authors:  G W Falk; M F Catalano; M V Sivak; T W Rice; J Van Dam
Journal:  Gastrointest Endosc       Date:  1994 Mar-Apr       Impact factor: 9.427

9.  Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus.

Authors:  R E Rudolph; T L Vaughan; B E Storer; R C Haggitt; P S Rabinovitch; D S Levine; B J Reid
Journal:  Ann Intern Med       Date:  2000-04-18       Impact factor: 25.391

10.  Flow cytometric DNA analysis and p53 protein expression show a good correlation with histologic findings in patients with Barrett's esophagus.

Authors:  A Giménez; A Minguela; P Parrilla; J Bermejo; D Pérez; J Molina; A M García; M A Ortiz; R Alvarez; L M de Haro
Journal:  Cancer       Date:  1998-08-15       Impact factor: 6.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.